A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SLE
- SLE (Systemic Lupus)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cullinan Therapeutics Inc.
- Last updated on ClinicalTrials.gov
- October 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- AARA Clinical Research · Avondale, AZ
- AARA Clinical Research · Tucson, AZ
Florida · 1
- Omega Research Group · Orlando, FL
Iowa · 1
- University of Iowa · Iowa City, IA
Massachusetts · 1
- Boston Children's Hospital · Boston, MA
New York · 2
- NYU Grossman School of Medicine · New York, NY
- University of Rochester Medical Center · Rochester, NY
Tennessee · 1
- Regional One Health · Memphis, TN
Texas · 2
- Stryde Research · Plano, TX
- Tranquil Clinical Research · Webster, TX
Utah · 1
- Intermountain Health · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.